Neutrophils enact lysis of antibody opsonized target tumor cells by utilizing the CD11b – CD18 interaction to form a cytotoxic synapse which leads to trogocytosis.  This process can be effectively blocked by blockade with either anti-CD11b or anti-CD18 mAbs, but is enhanced when SIRPa – CD47 blockade is employed. “Neutrophils Kill Antibody Opsonized Cancer Cells […]

“Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus” Stuart J, Stephen H Clarke, et al.  July 1, 2019 Journal of Immunology 203(1): 58-75.  Doi: htpps://doi.org.10.4049/jimmunol.1900043.   Relevant Ancell Products anti-human CD40 mAb Recombinant human CD40-muIg Recombinant human CD154-muCD8

We’ll be exhibiting at the American Immunology Association meeting in San Diego May 10-13 .  Visit us at booth # 417.   

Visit Ancell at booth 4668 at the American Association for Cancer Research meeting in Atlanta Sunday March 31st – Tuesday April 3.  We are co exhibiting with our friends at Incepix!

Anti-CD47 H5F9-G4 antibody blocks CD47 – SIRPa interaction and has been shown to restore anti-cancer immunity in mouse models.  In recent human studies, initial drug dose showed promising effect and was well tolerated in combination with Rituximab(anti-CD20) with side effects of anemia, headache and fatigue.   Relevant Ancell Products New anti-human CD47 mAb

The authors prove the concept that an anti-TCR Cb1 CAR cell based on the epitope of Jovi-1 anti-TCR Cb1 mAb can kill malignant T cell leukemic cells without destroying TCR Cb2 cells.  ”Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.” Paul M Maciocia, Martin A Pule, et al. (2017)

The authors surmise that the presence or absence of CD62L expression on these cells could be used as a diagnostic indicator of autoimmune diseases, such as Crohn. CD62L Is a Functional and Phenotypic Marker for Circulating Innate Lymphoid Cell Precursors  Yotam E. Bar-Ephraim, Reina E. Mebius et al.  J Immunol January 1, 2019, 202 (1)

Visit Ancell at the Autumn Immunology Conference in Chicago, booth T13  Fri Nov 16 through Mon Nov 19th !  We are proud to once again fund an Undergrad Outreach Sponsorship, as well as a Wallace Diversity Sponsorship.

CD47 is emerging as a promising intervention point in Cancer therapy. Head and Neck Squamous Cell Carcinoma:  Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma.  Wu L, Sun ZJ, et al. (2018) Oncoimmunology 7(4): e1397248. Doi: 10.1080/2162402X.2017.1397248. Glioma:  Blocking the CD47-SIRPα axis by delivery of anti-CD47

Anti-GITR is proving to be another useful intervention checkpoint in cancer therapy.   Abstract 3813: Development of JNJ-64164711, a low fucose anti-GITR antibody for enhanced depletion of tumor regulatory T cells (Tregs) Cam V. Holland, John Kehoe, Judith Hailey, Rupesh Nanjunda, Eilyn Lacy, Robin Ernst, Di Zhang, Sam Wu, Alexey Teplyakov, Weimin Li, Michelle Kinder,